Short Interest in Vyome Holdings, Inc. (NASDAQ:HIND) Increases By 220.8%

Vyome Holdings, Inc. (NASDAQ:HIND) was the recipient of a significant increase in short interest in January. As of January 30th, there was short interest totaling 260,650 shares, an increase of 220.8% from the January 15th total of 81,249 shares. Currently, 6.9% of the shares of the stock are sold short. Based on an average daily trading volume, of 4,310,075 shares, the short-interest ratio is currently 0.1 days. Based on an average daily trading volume, of 4,310,075 shares, the short-interest ratio is currently 0.1 days. Currently, 6.9% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e-)” rating on shares of Vyome in a research note on Monday, December 29th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $15.00.

Hedge Funds Weigh In On Vyome

A hedge fund recently bought a new stake in Vyome stock. Geode Capital Management LLC acquired a new stake in Vyome Holdings, Inc. (NASDAQ:HIND) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 11,934 shares of the company’s stock, valued at approximately $41,000. Geode Capital Management LLC owned about 0.21% of Vyome at the end of the most recent quarter. Institutional investors own 22.06% of the company’s stock.

Vyome Trading Down 0.8%

Shares of HIND traded down $0.02 during midday trading on Friday, hitting $2.59. 123,537 shares of the stock were exchanged, compared to its average volume of 1,701,124. Vyome has a 52-week low of $1.75 and a 52-week high of $305.00. The stock’s fifty day moving average is $3.34. The firm has a market cap of $14.61 million, a price-to-earnings ratio of -0.02 and a beta of 1.50.

Vyome (NASDAQ:HIND) last announced its earnings results on Friday, November 14th. The company reported ($3.12) EPS for the quarter. Vyome had a negative net margin of 270.58% and a negative return on equity of 423.39%. The firm had revenue of $0.04 million for the quarter.

About Vyome

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.